<!–
–>
Demand in the Covid-19 tests market has dramatically declined since its peak in Q4 2021. Additionally, while there was a spike in purchases of Covid-19 tests during December 2020 – January 2021 and December 2021 – January 2022, that spike did not occur during December 2022 – January 2023. However, despite the fact that there have been decreases in the number of confirmed Covid-19 cases, there is still a steady demand for testing. To put this in perspective, current GlobalData estimates show that the Covid-19 tests market revenue for January 2023 is equivalent to 70% of the market revenue for December 2020, when testing was in dire need.
While Covid-19 is no longer a pressing concern for many people due to vaccine rollouts and health and safety policies, a percentage of the population still takes these tests to monitor for potential infections, when in preparation for international travel, or due to working at companies that require employees to provide a negative test in order to return to work. This has resulted in a more resilient market than previously expected.
Cepheid continues to be the clear market leader in Covid-19 testing and has retained this status for the last 18 months, while other competitors such as F Hoffmann-La Roche and Abbott have gradually decreased their market share.
Cepheid’s rollout of products such as Xpert Xpress CoV-2/Flu/RSV plus and Xpert Xpress CoV-2plus has allowed the company to capitalise on concerns about multiple variants of Covid-19, which has been a key mechanism to its success. This product not only has enhanced gene coverage but also tests for multiple influenza-like illnesses. The adaptability of these rapid testing devices will likely benefit them not only in Covid-19 tests but in the overall in vitro diagnostics (IVD) market.
Since Covid-19 remains in an endemic status and the behaviour of the virus makes long-term immunity difficult, the need for testing is expected to be continuous, but not to remain at the same levels shown at the height of the Covid-19 pandemic. Companies, such as Cepheid, that can adapt their products to address the changing nature of the virus and future variants will make notable gains in this market.
<!– GPT AdSlot 3 for Ad unit 'Verdict/Verdict_In_Article' ### Size: [[670,220]] —
!– End AdSlot 3 –>
- SEO Powered Content & PR Distribution. Get Amplified Today.
- Platoblockchain. Web3 Metaverse Intelligence. Knowledge Amplified. Access Here.
- Source: https://www.medicaldevice-network.com/comment/covid-19-tests-market/
- :is
- 2020
- 2021
- 2022
- 2023
- a
- About
- Ad
- adapt
- Additionally
- address
- and
- AS
- At
- BE
- benefit
- CAN
- cases
- changing
- clear
- Companies
- company
- competitors
- Concern
- Concerns
- CONFIRMED
- continues
- continuous
- coverage
- COVID-19
- COVID-19 pandemic
- credit
- Current
- December
- december 2021
- Demand
- Despite
- Devices
- DID
- difficult
- dire
- dramatically
- during
- employees
- enhanced
- Equivalent
- estimates
- expected
- For
- future
- Gains
- GlobalData
- gradually
- Have
- Health
- height
- However
- HTTPS
- immunity
- in
- Infections
- International
- ITS
- January
- January 2021
- jpg
- Key
- Last
- leader
- levels
- likely
- long-term
- longer
- make
- MAKES
- many
- many people
- Market
- Market Leader
- mechanism
- Monitor
- months
- more
- multiple
- Nature
- Need
- negative
- notable
- number
- of
- on
- order
- Other
- overall
- pandemic
- Peak
- People
- percentage
- perspective
- plato
- Plato Data Intelligence
- PlatoData
- plus
- policies
- population
- potential
- previously
- Product
- Products
- provide
- purchases
- put
- rapid
- remain
- remains
- require
- resilient
- return
- revenue
- Safety
- same
- Share
- show
- shown
- shutterstock
- since
- Size
- spike
- Status
- steady
- Steve
- Still
- success
- such
- Take
- takes
- test
- Testing
- tests
- that
- The
- their
- Them
- These
- to
- travel
- unit
- Vaccine
- virus
- which
- while
- will
- Work
- working
- zephyrnet